Initially, there was a plan to administer the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) abemaciclib, which was ultimately not started due to persistent diarrhea and thrombocytopenia. This evidence concerns the gene CDK4 and Thrombocytopenia.